Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis

Hepatology

Volumn 56, Issue 4, 2012, Pages 1439-1447

  Ferlitsch, Monika ^a   Reiberger, Thomas ^a   Hoke, Matthias ^a   Salzl, Petra ^a   Schwengerer, Bernadette ^a   Ulbrich, Gregor ^a   Payer, Berit Anna ^a   Trauner, Michael ^a   Peck Radosavljevic, Markus ^a   Ferlitsch, Arnulf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ASCITES; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; END STAGE LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODYNAMICS; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PORTAL HYPERTENSION; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL; VARICOSIS;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84867212986     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25806     Document Type: Article

References (26)

1. Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis 2006; 26: 348-362.
2. Thabut D, Moreau R, Lebrec D. Non-invasive assessment of portal hypertension in patients with cirrhosis. HEPATOLOGY 2011; 53: 683-694.
3. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensusworkshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-768.
4. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. HEPATOLOGY 2007; 45: 1290-1297.
5. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231.
6. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46: 927-934.
7. Matei V, Rodríguez-Vilarrupla A, Deulofeu R, Colomer D, Fernández M, Bosch J, Garcia-Pagán JC. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. HEPATOLOGY 2006; 44: 44-52.
8. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJ, Fijnheer R. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 179-185.
9. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. HEPATOLOGY 2006; 44: 53-61.
10. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397.
11. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641.
12. La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011; 60: 1133-1138.
13. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. HEPATOLOGY 1995; 21: 1238-1247.
14. Homoncik M, Ferlitsch A, Ferenci P, Formann E, Jilma B, Gangl A, et al. Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plugformation and von Willebrand factor release in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005; 21: 49-55.
15. Pramhas S, Homoncik M, Ferenci P, Ferlitsch A, Scherzer T, Gangl A, Peck-Radosavljevic M. von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4. Antivir Ther 2010; 15: 831-839.
16. Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, et al. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol 2007; 102: 2495-2503.
17. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2011; 9: 602-608.
18. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
19. Knottnerus JA, Muris JW. Assessment of the accuracy of diagnostic tests: the cross-sectional study. J Clin Epidemiol 2003; 56: 1118-1128.
20. Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003; 52: 404-409.
21. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005; 11: 1167-1169.
22. Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. HEPATOLOGY 1996; 23: 1377-1383.
23. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91: 267-275.
24. Chandler WL, Peerschke EI, Castellone DD, Meijer P; NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135: 862-869.
25. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol 2011 Dec 15. doi: 10.1007/s00535-011-0517-4.
26. Abraldes JG, Villanueva C, Bañares R, Aracil C, Catalina MV, Garci A-Pagán JC, Bosch J; Spanish Cooperative Group for Portal Hypertension and Variceal Bleeding. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008; 48: 229-236.